Skip to main content
Midas Edge

Axsome Therapeutics Inc

For the period ended Dec 31, 2023. Filed Feb 23, 2024.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Feb 23, 2024

AXSM$133.96+1.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Table of Contents

Page
SPECIAL CAUTIONARY NOTICE REGARDING FORWARD-LOOKING STATEMENTS3
PART I
ITEM 1Business4
ITEM 1ARisk Factors42
ITEM 1BUnresolved Staff Comments100
ITEM 1CCybersecurity100
ITEM 2Properties101
ITEM 3Legal Proceedings101
ITEM 4Mine Safety Disclosures103
PART II
ITEM 5Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities104
ITEM 7Management’s Discussion and Analysis of Financial Condition and Results of Operations106
ITEM 7AQuantitative and Qualitative Disclosure About Market Risk121
ITEM 8Financial Statements and Supplementary Data121
ITEM 9Changes in and Disagreements with Accountants on Accounting and Financial Disclosure122
ITEM 9AControls and Procedures122
ITEM 9BOther Information123
ITEM 9CDisclosure Regarding Foreign Jurisdictions that Prevent Inspections123
PART III
ITEM 10Directors, Executive Officers and Corporate Governance124
ITEM 11Executive Compensation124
ITEM 12Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters124
ITEM 13Certain Relationships and Related Transactions and Director Independence124
ITEM 14Principal Accountant Fees and Services124
PART IV
ITEM 15Exhibits and Financial Statement Schedules125
Signatures132
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.